CYCC vs. OMEX

In the year-to-date period, CYCC achieves a -75.08% return, which is significantly lower than OMEX's 24.18% return. Over the past 10 years, CYCC has underperformed OMEX with an annualized return of -64.54%, while OMEX has yielded a comparatively higher -17.00% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Cyclacel Pharmaceuticals, Inc. (CYCC) and Odyssey Marine Exploration, Inc. (OMEX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CYCC Sharpe Ratio is -0.83, which is lower than the OMEX Sharpe Ratio of -0.28. The chart below compares the historical Sharpe Ratios of CYCC and OMEX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

CYCC's dividend yield for the trailing twelve months is around 165.52%, while OMEX has not paid dividends to shareholders.

The maximum CYCC drawdown since its inception was -100.00%, roughly equal to the maximum OMEX drawdown of -99.70%. Use the drawdown chart below to compare losses from any high point for CYCC and OMEX.

The current volatility for Cyclacel Pharmaceuticals, Inc. (CYCC) is 56.51%, while Odyssey Marine Exploration, Inc. (OMEX) has a volatility of 69.54%. This indicates that CYCC experiences smaller price fluctuations and is considered to be less risky than OMEX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Cyclacel Pharmaceuticals, Inc. and Odyssey Marine Exploration, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.